ArticleBiomedical reports2025
Prospective study of cesarean scar pregnancy associated with increased MCP-1 and cholesterol synthesis.
Article in Biomedical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study, it was investigated whether gestational trophoblast localization at the cesarean scar was associated with increased monocyte chemoattractant protein-1 (MCP-1) and cholesterol synthesis in women's blood and decidual stromal cells. Patients who underwent abortion at 6-10 weeks of gestation were divided into three groups: cesarean scar pregnancy (CSP), normal intrauterine pregnancy without history of cesarean section (NP), and normal intrauterine pregnancy after cesarean section (NPACS). Blood and decidual tissue at the localization of the gestational sacs were collected from the patients, and RNA sequencing, PCR and ELISA were used to detect differences in the expression of thrombin receptor protease-activated receptor-1 (PAR-1), MCP-1, CCR2, chemokine (C-C motif) receptor 2 (CCR2) and cholesterol synthesis-related proteins sterol regulatory element-binding protein 2 (SREBP2), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and hydroxy-methyl-glutaryl Coenzyme A synthase (HMGCS). The expression of PAR-1, MCP-1, CCR2, SREBP2, HMGCR and HMGCS in the blood and the decidual stromal cells at the localization of the gestational sac was significantly higher in women with CSP than in the other two groups of patients, whereas the expression of these molecules between NP group and NPACS were not significantly different, and the total blood cholesterol levels of women with cesarean scar pregnancies were significantly higher than those of the other two groups. The development of CSP was associated with a high cholesterol environment and increased MCP-1 expression in women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.